Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer

International Journal of Cancer

Volumn 74, Issue 1, 1997, Pages 138-140

  Paulsen, T ^a   Aas, T ^a   Borresen, A L ^a   Varhaug, J E ^a   Lonning, P E ^a   Akslen, L A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; TUMOR SUPPRESSOR PROTEIN P53; VON WILLEBRAND FACTOR;

EID: 0030916710     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970220)74:1<138::AID-IJC23>3.0.CO;2-A     Document Type: Letter

References (23)